
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics Inc. benefits from a robust market for its integrated solutions, as indicated by the meaningful increase in Chromium reaction volumes, despite anticipated pricing pressures. The company's consumables are projected to grow significantly faster than instrument revenue, with estimates suggesting a 5-19x increase per platform by 2027. This growth trajectory reflects the ongoing demand for advanced biological analysis tools, positioning 10x Genomics favorably within the life science technology market.
Bears say
10x Genomics Inc has reported a contraction in 2024, with revenues impacted by double-digit pricing pressure and flat to modestly lower volumes, leading to a bleak growth outlook that does not expect to improve until 2027. Additionally, the company experienced weaker-than-expected Q4 results with an earnings per share miss and a full-year revenue outlook that fell below analyst expectations. Since its peak stock prices in 2021, 10x Genomics’s stock has declined over 90%, indicating that performance has not met market expectations, contributing to a negative outlook for the company's financial stability.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares